DOI: 10.36347/sjams.2016.v04i04.042

Pages: 1323-1327

Acinetobacter baumannii is emerging as an important pathogen causing hospital acquired infections. It has been reported as the cause of serious infectious diseases involving mostly patients with impaired host defences, especially in intensive care units (ICUs). Emergence of metallo –β- lactamases (MBL) producing multidrug resistant (MDR) A. baumannii is a matter of concern in an intensive care unit (ICU). The present study was directed to find out the incidence, antibiotic susceptibility and metallo β lactamases production of Acinetobacter baumannii isolated from various clinical samples, in an intensive care unit. Material and Methods in this study Isolation of Acinetobacter baumannii from various clinical samples was done over a period of 1 year. The isolates were tested for antibiotic sensitivity as per conventional methods. Imipenem resistant isolates were further tested for MBL production by double disk synergy test and MBL E test. In Results the Total number of Acinetobacter baumannii isolates from clinical samples was 42. Maximum number of A. baumannii were isolated from endotracheal aspirates, i.e. 20 (47.6%), followed by blood, 11(26.19%). All 42(100%) isolates were multidrug resistant. A total of 35(83.3%) isolates were Imipenem resistant, among which, 31(73.8%) were MBL producers. MBL producers were more resistant to commonly used antibiotics than its non MBL producing counter parts. All isolates were susceptible to Colistin (10 μg). In Conclusion Multidrug resistant, metallo β lactamases producing Acinetobacter baumannii infections are on the rise in intensive care units. Colistin is very effective against such isolates. The analysis of susceptibility patterns will be useful in understanding the epidemiology and help in treatment and control of the spread of resistant isolates.